Biosimilar/Generic Injectable Pens Market
完整報告名稱與涵蓋範圍
Biosimilar/Generic Injectable Pens Market Size, Share & Trends Analysis Report By Drug used in pens, By Type (Disposable and Reusable Biosimilar Injectable Pens), By Dosage (Fixed-Dose and Variable Dose), By Therapies, By Distribution Channel , Region, And Segment Forecasts, 2025-2034
報告摘要
The global Biosimilar/Generic Injectable Pens Market is anticipated to witness considerable expansion over the coming years.
The Biosimilar/Generic Injectable Pens sector involves approved by respective regulatory bodies because of its clinical similarity to already approved biological products. This domain has witnessed considerable transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is bolstered by growing appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region anticipated to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biosimilar/Generic Injectable Pens Market Snapshot
Chapter 4. Global Biosimilar/Generic Injectable Pens Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental OpportNo.Of. Unitsy Analysis (US$ MN), 2025-2034
4.8. Global Biosimilar/Generic Injectable Pens Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on BIOSIMILAR/GENERIC INJECTABLE PENS MARKET Industry Trends
Chapter 5. Biosimilar/Generic Injectable Pens Market Segmentation 1: By Drug Used in Pens, Estimates & Trend Analysis
5.1. Market Share by Drug Used in Pens, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Volume (No.Of. Units)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Used in Pens:
5.2.1. Biosimilar
5.2.2. Generics
Chapter 6. Biosimilar/Generic Injectable Pens Market Segmentation 2: By Type, Estimates & Trend Analysis
6.1. Market Share by Type, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Volume (No.Of. Units)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
6.2.1. Disposable biosimilar Injectable Pens
6.2.2. Reusable biosimilar Injectable Pens
Chapter 7. Biosimilar/Generic Injectable Pens Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Volume (No.Of. Units)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
7.2.4. Direct Sales (B2B)
Chapter 8. Biosimilar/Generic Injectable Pens Market Segmentation 4: By Dosage, Estimates & Trend Analysis
8.1. Market Share by Dosage, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Volume (No.Of. Units)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Dosage:
8.2.1. Fixed Dose
8.2.2. Variable Dose
Chapter 9. Biosimilar/Generic Injectable Pens Market Segmentation 5: By Therapies, Estimates & Trend Analysis
9.1. Market Share by Therapies, 2024 & 2034
9.2. Market Size (Value (US$ Mn) & Volume (No.Of. Units)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapies:
9.2.1. Diabetes
9.2.2. Oncology
9.2.3. Autoimmune Diseases
9.2.4. Growth Hormone Deficiency
9.2.5. Other (e.g., Osteoporosis)
Chapter 10. Biosimilar/Generic Injectable Pens Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Biosimilar/Generic Injectable Pens Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Drug Used in Pens, 2021-2034
10.2.3. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Type, 2021-2034
10.2.4. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Distribution Channel, 2021-2034
10.2.5. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Dosage, 2021-2034
10.2.6. North America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Therapies, 2021-2034
10.3. Europe
10.3.1. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Drug Used in Pens, 2021-2034
10.3.3. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Type, 2021-2034
10.3.4. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Distribution Channel, 2021-2034
10.3.5. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Dosage, 2021-2034
10.3.6. Europe Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Therapies, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Drug Used in Pens, 2021-2034
10.4.3. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Type, 2021-2034
10.4.4. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Distribution Channel, 2021-2034
10.4.5. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts By Dosage, 2021-2034
10.4.6. Asia Pacific Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Therapies, 2021-2034
10.5. Latin America
10.5.1. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Drug Used in Pens, 2021-2034
10.5.3. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Type, 2021-2034
10.5.4. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Distribution Channel, 2021-2034
10.5.5. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Dosage, 2021-2034
10.5.6. Latin America Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Therapies, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Drug Used in Pens, 2021-2034
10.6.3. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Type, 2021-2034
10.6.4. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Distribution Channel, 2021-2034
10.6.5. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Dosage, 2021-2034
10.6.6. Middle East & Africa Biosimilar/Generic Injectable Pens Market Revenue (US$ Mn) & Volume (No.Of. Units) Estimates and Forecasts by Therapies, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
Biosimilar and Generic Drug Companies
11.2.1. Sandoz International GmbH (Novartis)
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Pfizer Inc. (via Hospira)
11.2.3. Amgen Inc.
11.2.4. Teva Pharmaceutical Industries Ltd.
11.2.5. Biocon Ltd.
11.2.6. Celltrion Healthcare Co., Ltd.
11.2.7. Reddy's Laboratories Ltd.
11.2.8. Eli Lilly and Company
11.2.9. Civica Rx
11.2.10. Fresenius Kabi AG
11.2.11. Other prominent players
Injectable Pen Device Companies
11.2.12. Ypsomed Holding AG
11.2.13. SHL Group (SHL Medical AG)
11.2.14. Owen Mumford Ltd.
11.2.15. Haselmeier
11.2.16. Gerresheimer AG
11.2.17. Phillips Medisize
11.2.18. DCA Design (for Sanofi)
11.2.19. Jiangsu Delfu Medical Device Co., Ltd.
11.2.20. Emperra GmbH
11.2.21. Companion Medical, Inc.
11.2.22. Digital Medics Pty Ltd
11.2.23. Copernicus
11.2.24. Diamesco Co., Ltd.
11.2.25. Other prominent players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們